{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:36:37Z","timestamp":1792658197869,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P50 CA098258"],"award-info":[{"award-number":["P50 CA098258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ygyno.2015.03.042","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T21:05:23Z","timestamp":1428786323000},"page":"386-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation \u2014 An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"137","clinical-trial-number":[{"clinical-trial-number":"nct01540565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01844986","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01847274","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01874353","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01968213","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Robert L.","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bell-McGuinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.03.042_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/279847","article-title":"The origin of variation","volume":"56","author":"Bridges","year":"1922","journal-title":"Am. Nat."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0015","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","article-title":"Integrating genetic approaches into the discovery of anticancer drugs","volume":"278","author":"Hartwell","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrclinonc.2010.116","article-title":"Making the best of PARP inhibitors in ovarian cancer","volume":"7","author":"Banerjee","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/jmedgenet-2013-102015","article-title":"Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants","volume":"51","author":"Jervis","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0035","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0045","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0055","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0060","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.ygyno.2015.03.042_bb0065","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1200\/jco.2012.30.15_suppl.5001","article-title":"Olaparib plus paclitaxel and carboplatin followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label Phase II study","volume":"30","author":"Oza","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0070","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0075","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0080","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ygyno.2015.03.042_bb0085","doi-asserted-by":"crossref","first-page":"OF2","DOI":"10.1158\/2159-8290.CD-NB2013-182","article-title":"Positive results for drug combo veliparib in I-SPY 2 trial","volume":"4","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0090","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-11-2821","article-title":"A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas","volume":"18","author":"Kummar","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0095","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0100","first-page":"1213","article-title":"Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant","volume":"25","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0110","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0120","series-title":"Technical Report 04-01","article-title":"Adapting rejection boundaries when the targeted accrual is not attained in 2-stage phase II clinical trials","author":"Sill","year":"2001"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00404-010-1462-9","article-title":"Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer","volume":"283","author":"Bryant","year":"2011","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0135","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/IGC.0b013e318217b30b","article-title":"Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?","volume":"21","author":"Ledermann","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0140","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/annonc\/mdt384","article-title":"PARP Inhibitors for BRCA1\/2 mutation-associated and BRCA-like malignancies","volume":"25","author":"Lee","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0150","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0155","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.molonc.2012.12.007","article-title":"BRCA1\/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation","volume":"7","author":"Stordal","year":"2013","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0165","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/nm.3369","article-title":"Mechanisms of resistance to therapies targeting BRCA-mutant cancers","volume":"19","author":"Lord","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0170","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0175","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0180","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0185","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molcel.2012.02.015","article-title":"BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair","volume":"46","author":"Bunting","year":"2012","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2015.03.042_bb0195","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2015.03.042_bb0200","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2015.03.042_bb0205","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815007593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T10:05:05Z","timestamp":1668593105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815007593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0090825815007593"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation \u2014 An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}